ASCO Annual Meeting

Cabozantinib Associated With Higher Rates of Certain AEs in Advanced Kidney Cancer

June 11, 2021

While cabozantinib exposure was not a predictor of progression-free survival, it was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma who are given frontline cabozantinib plus nivolumab.